Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

ResMed Reports NPAT of $195.1m for the Three Months Ending 30 June 2021

22 Sep 2021  |  14:20:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: ResMed Announces Results for the Fourth Quarter of FY2021

ResMed reported NPAT of $195.1m for three months ended 30 June 2021. Revenue from ordinary activities were $876.10m, up 14% from last year. Diluted EPS was 133 cents compared to 122 cents last year. Net operating cash flow was $736.72m compared to $802.26m last year. The dividend declared was 42 cents compared with nil cents last year.

ResMed Quarterly Results to 30 June 2021

3 Months to 30 June 2021 (US$'000) Year to 30 June 2020 (US$'000)
Revenue 876,103 770,343
Pre-Tax Profit 239,210 212,094
Net Profit 195,098 177,835
Operating Cash Flow 736,718 802,255
Dividend (cents) 42 nil
Diluted EPS (cents) 133 122
NTA (cents) nil nil
Please click here for full details

See more ASX300 News Announcements